Yahoo Finance

Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical ...

3 out of 4 (75%) patients experienced tumor shrinkage at 2 months 1 out of 4 (25%) patients experienced tumor control at 2 months 1 out of 4 patients remain on IMX-110 + tislelizumab therapy as of ...
Yahoo Finance

Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the Lowest Dose of ...

LOS ANGELES, May 03, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company ...
PharmiWeb

IMX Data Achieves SOC 2 Certification, Reinforcing Commitment to Data Security and Trust

NEW YORK--(BUSINESS WIRE)--IMX Data, a leading provider of comprehensive healthcare claims data for institutional clients, today announced that it has successfully achieved SOC 2 certification, ...
ksn.com

Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical ...

Tumor shrinkage was observed in 3 out of 4 (75%) patients; 1 out of 4 (25%) experienced tumor control as of the July 7, 2023 clinical data cutoff date. All patients had stage IV relapsed/refractory ...